← Statins × lipids

Observational studyEuropean heart journal. Cardiovascular pharmacotherapy2025

Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability.

Seung-Jun Lee et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 6,215 people · 2025

Not counted

Lowered lipids

−19%−26% to −12%

Bigger than 4 in 10 on the map

As reported

HR 0.81, 95% CI 0.74–0.88

Not counted

Lowered adverse events & safety

−19%−27% to −10%

Bigger than 5 in 10 for adverse events & safety

As reported

HR 0.81, 95% CI 0.73–0.90

Not counted

Lowered adverse events & safety

−20%−30% to −8%

Bigger than 5 in 10 for adverse events & safety

As reported

HR 0.80, 95% CI 0.70–0.92

Three numbers in the abstract

the abstract, start to end

… monotherapy; hazard ratio [HR] 0.81, 95% confidence interval [CI] …

… discontinuation (10.0% vs. 8.4%, HR 0.81, 95% CI 0.73-0.90, P < 0.001) and new-onset diabetes requiring medication (8.8% vs. 7.0%, HR 0.80, 95% CI 0.70-0.92, P = 0.002).

← favours treatmentfavours comparator →
could be chance
Lipids
HR 0.810.74–0.88
Adverse events & safety
HR 0.810.73–0.90
Adverse events & safety
HR 0.800.70–0.92
StatinsLipidsAdverse events & safety
1 / 3

10 papers cite it

2024
2025
2026
this paperpooled itcites it

The trial

NCT04715594350,000 enrolled2019
Full record →Abstract, authors, funding and every citing paper · PMID 37951292